Choose2Quit: Improving Equity in Smoking Cessation for Low Income Adults

Tobacco Use Clinical Trial

Official title:

Choose2Quit: Improving Equity in Smoking Cessation for Low Income Adults

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT05612152
• Other study ID #: RSG-18-137-01-CPPB
• Status: Not yet recruiting
• Phase: N/A
• Start date: November 1, 2022
• Est. completion date: July 31, 2024

Study information

• Verified date: November 2022
• Source: Oregon Health and Science University
• Contact: Susan Flocke
• Phone: 216 965 5538
• Email: flocke[@]ohsu.edu
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The goal of this study is to evaluate the effectiveness of a tobacco treatment navigator to improve primary care patient engagement in tobacco cessation support. We compare an ask, advise and connect to the quitline approach vs. the novel tobacco treatment navigator approach on the primary outcomes of receipt of tobacco cessation counseling sessions and receipt of tobacco cessation medications.

Description:

Our novel intervention, Choose2Quit, builds on our prior successes with the Ask, Advice, Connect study, but now 1) allows personalized choice of counseling modality (phone, text, web, in-person); 2) conveys the value and low/no-cost availability of medications to support quit attempt success and sends providers the patient's request in e-prescription to transmit to patient's pharmacy; 3) assesses patient's need to manage social barriers to quitting by linking them to Unite-US; and 4) uses an initial phone contact from a recognizable local number, will increase the engagement of patients in cessation treatment and in tobacco cessation. This study aims to:

1. Test the effect of a traditional eReferral vs. a Choose2Quit personalized guidance and choice approach on the ability to contact patients, and the proportion of patients that initiate tobacco cessation treatment, use tobacco cessation medications and make quit attempts.

2. Assess the impact of each intervention arm on equitable engagement in tobacco cessation treatment, medication use and quit outcomes across gender, race and age groups.

3. Evaluate intervention experience from the patient perspective.

4. Evaluate the cost to implement, and per engagement in each of the intervention arms.

The study is accomplished using a 2-arm randomized trial. Randomization into the traditional eReferral vs. Choose2Quit intervention arms will occur at the patient level with a 1:1 group assignment. Individuals that are ready to quit in the next 30 days and are interested in being connected with tobacco cessation resources will be randomized. Randomization of eligible patients occurs automatically with an electronic health record algorithm that routes the eReferral to the Quitline (traditional eReferral) or the Choose2Quit intervention. The Ask-Advise-Connect process is exactly the same for medical assistants; medical assistants and patients are blind to group assignment

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 1600
• Est. completion date: July 31, 2024
• Est. primary completion date: February 28, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• patient care visit to one of the participating primary care clinics during the study period

• reports current tobacco use

• reports interest in quitting tobacco in the next 30 days

• accepts offer of referral to tobacco cessation support

Exclusion Criteria:

• not interested in quitting in next 30 days

• not interested in assistance

Related Conditions & MeSH terms

• Tobacco Use

Intervention

Other:
• Referral to Quitline
An electronic referral to the state quitline is placed. This prompts the quitline to proactively call the patient to enroll in counseling services.
• Choose2Quit
An electronic referral to the Choose2quit tobacco cessation navigator is placed. This prompts the navigator to call the patient to review options for tobacco cessation counseling, tobacco cessation medications and other supports.

Locations

Country	Name	City	State
n/a

Sponsors (3)

Lead Sponsor	Collaborator
Oregon Health and Science University	Case Western Reserve University, MetroHealth Health System

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	receipt of tobacco cessation counseling	receipt of 1 or more tobacco cessation counseling sessions from referral sources	4 weeks after referral
Primary	receipt of tobacco cessation medications	documentation of orders for nicotine replacement therapy, varenicline or bupropion in electronic health record	within 4 weeks after referral
Secondary	7-day point prevalence abstinence	7-day point prevalence abstinence from tobacco use	8 weeks after referral